Cargando…

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer

To evaluate the feasibility of amrubicin plus cisplatin (AP) following chemoradiotherapy for limited‐disease small‐cell lung cancer, chemo‐naïve patients aged 20–70 years with a performance status of 0 or 1 and normal organ functions were treated with etoposide 100 mg/m(2) on days 1–3, cisplatin 80...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sekine, Ikuo, Sumi, Minako, Satouchi, Miyako, Tsujino, Kayoko, Nishio, Makoto, Kozuka, Takuyo, Niho, Seiji, Nihei, Keiji, Yamamoto, Nobuyuki, Harada, Hideyuki, Ishikura, Satoshi, Tamura, Tomohide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814250/ https://www.ncbi.nlm.nih.gov/pubmed/26748638 http://dx.doi.org/10.1111/cas.12875

Ejemplares similares

Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Ito, Masami, et al.
Publicado: (2012)

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma
por: Sakaida, Emiko, et al.
Publicado: (2017)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver
por: Isobe, Taichi, et al.
Publicado: (2009)

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
por: Horita, Nobuyuki, et al.
Publicado: (2016)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Tumor‐selective Distribution of an Active Metabolite of the 9‐Aminoanthracycline Amrubicin
por: Noguchi, Toshihiro, et al.
Publicado: (1998)

Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age
por: Murofushi, Keiko Nemoto, et al.
Publicado: (2015)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
por: Imamura, Fumio, et al.
Publicado: (2015)

In vivo Efficacy and Tumor‐selective Metabolism of Amrubicin to Its Active Metabolite
por: Noguchi, Toshihiro, et al.
Publicado: (1998)

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
por: Yamamoto, Michiko, et al.
Publicado: (2009)

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
por: Ogawara, Daiki, et al.
Publicado: (2010)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
por: Ding, Qian, et al.
Publicado: (2013)

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study
por: Sone, Hideyuki, et al.
Publicado: (2018)

A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
por: Sasaki, Tomonari, et al.
Publicado: (2018)

Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
por: Tachihara, Motoko, et al.
Publicado: (2021)

Radiation therapy for localized duodenal low-grade follicular lymphoma
por: Harada, Arisa, et al.
Publicado: (2016)

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
por: Kushiro, Kohei, et al.
Publicado: (2022)

Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer
por: Hisakane, Kakeru, et al.
Publicado: (2017)

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
por: Horinouchi, Hidehito, et al.
Publicado: (2019)

Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies
por: Saka, Hideo, et al.
Publicado: (2020)

Incremental low doses of amrubicin for the treatment of bone marrow metastasis in small cell lung cancer
por: Asai, Nobuhiro, et al.
Publicado: (2013)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
por: Watanabe, Kageaki, et al.
Publicado: (2021)

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2023)

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review
por: Nishiyama, Akihiro, et al.
Publicado: (2021)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status
por: Igawa, Satoshi, et al.
Publicado: (2018)

Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Long‐term outcomes of high‐dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall‐cell lung cancer
por: Ohnishi, Kayoko, et al.
Publicado: (2021)

Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells
por: Yamaoka, Takashi, et al.
Publicado: (1998)

A questionnaire-based survey on 3D image-guided brachytherapy for cervical cancer in Japan: advances and obstacles
por: Ohno, Tatsuya, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vancc5o93r022hqu063fvm6fq5